×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CTSO – cytosorbents corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CTSO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/26
03:24 pm
ctso
Cytosorbents (CTSO) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.
Low
Report
Cytosorbents (CTSO) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.
3/25
11:23 pm
ctso
CytoSorbents Corp (CTSO) Q4 2025 Earnings Call Highlights: Navigating Growth and Regulatory ... [Yahoo! Finance]
High
Report
CytoSorbents Corp (CTSO) Q4 2025 Earnings Call Highlights: Navigating Growth and Regulatory ... [Yahoo! Finance]
3/25
06:48 pm
ctso
Cytosorbents outlines cash flow breakeven path for second half of 2026 amid international sales growth [Seeking Alpha]
Low
Report
Cytosorbents outlines cash flow breakeven path for second half of 2026 amid international sales growth [Seeking Alpha]
3/25
04:42 pm
ctso
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
3/25
04:05 pm
ctso
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
High
Report
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
3/19
09:44 am
ctso
CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
Medium
Report
CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
3/5
07:22 am
ctso
CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
Low
Report
CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
3/5
07:00 am
ctso
CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Low
Report
CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/2
07:00 am
ctso
Form 8-K Cytosorbents Corp For: Apr 01
Medium
Report
Form 8-K Cytosorbents Corp For: Apr 01
3/30
07:05 am
ctso
Form 10-K Cytosorbents Corp For: Dec 31
Low
Report
Form 10-K Cytosorbents Corp For: Dec 31
3/25
04:28 pm
ctso
Form 8-K Cytosorbents Corp For: Mar 25
High
Report
Form 8-K Cytosorbents Corp For: Mar 25
2/13
05:56 pm
ctso
Form SCHEDULE 13G/A Cytosorbents Corp Filed by: AVENIR CORP
Low
Report
Form SCHEDULE 13G/A Cytosorbents Corp Filed by: AVENIR CORP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/25
CytoSorb® Used to Treat More than 70 Critically-Ill COVID-19 Patients and Specifically Added to Coronavirus Treatment Guidelines in Italy and Panama
29.3%
8/15 CytoSorbents Receives Renewal of CytoSorb® CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022 15.8%
3/12 Form 4 Cytosorbents Corp For: Mar 10 Filed by: Capponi Vincent 14.3%
3/31 CytoSorb® Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care 13.7%
4/24 Cytosorbents Corp (NASDAQ: CTSO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 12.2%
3/9 Cytosorbents Corp (NASDAQ: CTSO) had its "buy" rating re-affirmed by analysts at Dawson James. They now have a price target on the stock, up previously from . 11.1%
3/3 Form 4 Cytosorbents Corp For: Feb 28 Filed by: Jones Edward Raymond 8.2%
3/5 Form 10-K Cytosorbents Corp For: Dec 31 7.7%
4/16 Form 8-K Cytosorbents Corp For: Apr 10 7.4%
12/6 Form 4 Cytosorbents Corp For: Dec 06 Filed by: Chan Phillip P. 7.2%
8/15 CytoSorbents Receives Renewal of CytoSorb® CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022 15.8%
3/12 Form 4 Cytosorbents Corp For: Mar 10 Filed by: Capponi Vincent 14.3%
3/31 CytoSorb® Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care 13.7%
4/24 Cytosorbents Corp (NASDAQ: CTSO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 12.2%
3/9 Cytosorbents Corp (NASDAQ: CTSO) had its "buy" rating re-affirmed by analysts at Dawson James. They now have a price target on the stock, up previously from . 11.1%
3/3 Form 4 Cytosorbents Corp For: Feb 28 Filed by: Jones Edward Raymond 8.2%
3/5 Form 10-K Cytosorbents Corp For: Dec 31 7.7%
4/16 Form 8-K Cytosorbents Corp For: Apr 10 7.4%
12/6 Form 4 Cytosorbents Corp For: Dec 06 Filed by: Chan Phillip P. 7.2%
TOP News Decliners
8/6
Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha]
-14.1%
1/28 CytoSorbents latest entry in coronavirus rally; shares up 17% premarket [Seeking Alpha] -12.3%
2/28 CytoSorb Shipment Arrives in Designated Mainland China Hospitals to Treat Cytokine Storm in Critically-ill Patients with COVID-19 Coronavirus Infection -11.5%
4/28 CytoSorbents to Report Q1 2020 Operating and Financial Results -9.8%
3/2 CytoSorbents Highlights Recent Publication Using CytoSorb during Cardiac Surgery for Infective Endocarditits -8.8%
4/29 Cytosorbents: COVID-19 Has Presented A Bullish Opportunity [Seeking Alpha] -8.6%
11/25 CytoSorbents Changes Contract Research Organizations and Temporarily Pauses Enrollment in REFRESH 2-AKI Study -7.4%
2/27 CytoSorbents to Report Fiscal 2019 Operating and Financial Results and to Present at Cowen 40th Annual Healthcare Conference -7.1%
11/5 Q3/2019 9/30/2019 EPS -0.210 ZacksConsensus -0.140 ActVsEst (0.070) - Miss -6.9%
8/26 Form S-8 Cytosorbents Corp -6.7%
1/28 CytoSorbents latest entry in coronavirus rally; shares up 17% premarket [Seeking Alpha] -12.3%
2/28 CytoSorb Shipment Arrives in Designated Mainland China Hospitals to Treat Cytokine Storm in Critically-ill Patients with COVID-19 Coronavirus Infection -11.5%
4/28 CytoSorbents to Report Q1 2020 Operating and Financial Results -9.8%
3/2 CytoSorbents Highlights Recent Publication Using CytoSorb during Cardiac Surgery for Infective Endocarditits -8.8%
4/29 Cytosorbents: COVID-19 Has Presented A Bullish Opportunity [Seeking Alpha] -8.6%
11/25 CytoSorbents Changes Contract Research Organizations and Temporarily Pauses Enrollment in REFRESH 2-AKI Study -7.4%
2/27 CytoSorbents to Report Fiscal 2019 Operating and Financial Results and to Present at Cowen 40th Annual Healthcare Conference -7.1%
11/5 Q3/2019 9/30/2019 EPS -0.210 ZacksConsensus -0.140 ActVsEst (0.070) - Miss -6.9%
8/26 Form S-8 Cytosorbents Corp -6.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: